Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
APLM 
Apollomics Inc. Class A Ordinary Shares (APLM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: APLM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.83% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.11M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 0.89 | 52 Weeks Range 3.66 - 20.98 | Updated Date 09/17/2025 |
52 Weeks Range 3.66 - 20.98 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -52.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 1007.39% |
Management Effectiveness
Return on Assets (TTM) -75.07% | Return on Equity (TTM) -233.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17305978 | Price to Sales(TTM) 131.85 |
Enterprise Value 17305978 | Price to Sales(TTM) 131.85 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 2143350 | Shares Floating 542075 |
Shares Outstanding 2143350 | Shares Floating 542075 | ||
Percent Insiders - | Percent Institutions 0.67 |
Upturn AI SWOT
Apollomics Inc. Class A Ordinary Shares
Company Overview
History and Background
Apollomics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of immuno-oncology and targeted therapies to treat multiple cancers. Founded in 2015, it aims to address unmet medical needs in oncology by bringing innovative and effective therapies to patients globally.
Core Business Areas
- Drug Development: Focuses on the discovery and development of novel oncology therapeutics, including immuno-oncology and targeted therapies.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in cancer patients.
- Commercialization: Aims to commercialize its approved drugs globally, primarily through partnerships and strategic alliances.
Leadership and Structure
Apollomics is led by a team of experienced pharmaceutical executives and scientists. The company has a board of directors overseeing its strategic direction. The organizational structure includes research and development, clinical operations, commercial planning, and finance departments.
Top Products and Market Share
Key Offerings
- APL-101: A targeted therapy being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors. Currently in clinical trials. Market share data is not yet applicable as the drug is not yet approved. Competitors include pharmaceutical companies with marketed NSCLC therapies, such as AstraZeneca (AZN) and Merck (MRK).
- APL-106: An immuno-oncology therapy being developed to enhance immune responses against cancer cells. Currently in clinical trials. Market share data is not yet applicable as the drug is not yet approved. Competitors include companies with established immuno-oncology therapies, such as Bristol Myers Squibb (BMY) and Roche (RHHBY).
Market Dynamics
Industry Overview
The oncology market is a rapidly growing segment of the pharmaceutical industry, driven by increasing cancer incidence, aging populations, and advances in drug development. Immuno-oncology and targeted therapies are key growth areas.
Positioning
Apollomics aims to establish itself as a key player in the oncology market through the development and commercialization of innovative therapies. Its competitive advantage lies in its focus on novel targets and its strategic partnerships.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars annually. Apollomics is positioned to capture a portion of this TAM by developing and commercializing innovative cancer therapies.
Upturn SWOT Analysis
Strengths
- Innovative drug development pipeline
- Experienced management team
- Strategic partnerships
- Focus on high-growth oncology market
Weaknesses
- Limited commercial infrastructure
- Dependence on clinical trial success
- High R&D expenses
- Significant competition from established pharmaceutical companies
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or assets
- Strategic alliances with larger pharmaceutical companies
- Accelerated drug development timelines through regulatory pathways
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
Competitive Landscape
As a private company, Apollomics faces competition from large pharmaceutical companies and other biotech firms in the oncology space. Its success depends on differentiating its therapies and effectively commercializing them.
Growth Trajectory and Initiatives
Historical Growth: Unavailable due to lack of public financials.
Future Projections: Future growth depends on the success of its clinical trials and commercialization efforts. Analyst estimates are unavailable for a private company.
Recent Initiatives: Recent initiatives include advancing its clinical trial programs for APL-101 and APL-106 and seeking partnerships to expand its pipeline and commercial reach.
Summary
Apollomics is a biopharmaceutical company focused on developing innovative oncology therapies. It is still in the early stages of development with drugs in clinical trials. The company faces significant competition and risks associated with clinical trial success. Its future depends on advancing its pipeline and securing strategic partnerships to commercialize its therapies, but given its private status this analysis cannot be as strong.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Industry Reports
Disclaimers:
This analysis is based on limited publicly available information and is subject to change. Financial data is not available for this private company, leading to a less complete analysis. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apollomics Inc. Class A Ordinary Shares
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2021-11-26 | CEO & Chairman of the Board Mr. Hung-Wen Chen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.apollomicsinc.com |
Full time employees 13 | Website https://www.apollomicsinc.com | ||
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.